INCYTE CORP Principal Accounting Officer Tray Thomas reported two tax-withholding dispositions of common stock related to restricted stock unit settlements, totaling 1,790 shares on July 14–15, 2026. After these withholdings, Thomas holds 18,865 shares directly, including 10,236 shares issuable from unvested restricted stock units.
INCYTE CORP executive Steven H. Stein, CMO & Head of Late-Stage Development, reported multiple common stock transactions. On July 15, 2026, he completed an open-market sale of 28,237 shares at $113.05 per share. On July 14 and 15, a total of 24,918 shares were disposed of through automatic tax withholding tied to the settlement of restricted stock units (RSUs) and earned performance shares, rather than discretionary market sales. Following the reported open-market sale, he reported holding 26,083 shares of common stock directly, and his beneficial ownership figure includes 19,540 shares issuable from unvested RSUs and earned performance-share awards.
Incyte Corp executive Mohamed Khairie, EVP and Head of U.S. Commercial, reported a tax-related share disposition. On 2026-07-15, 1,099 common shares were automatically withheld by the company at $115.09 per share to satisfy RSU tax withholding obligations. Following this withholding, Khairie holds 65,033 shares directly, including 63,940 shares issuable from unvested restricted stock units.
A holder of INCY common stock filed a notice to sell 28,237 common shares through Morgan Stanley Smith Barney LLC on NASDAQ, with an associated value of $3,192,254.97 and an intended sale date of July 15, 2026. The securities to be sold consist of performance shares and restricted stock awards acquired from the issuer in July 2026, and the filing cites 199,782,155 common shares outstanding as context.
INCYTE CORP executive Patrick A. Mayes had 350 shares of common stock withheld by the company to cover tax obligations tied to restricted stock units. The withholding price was $116.86 per share. After this non-market tax-withholding event, he directly holds 59,661 shares of common stock.
A footnote also notes 58,730 additional shares are issuable from unvested restricted stock units, which are not yet settled into common stock.
INCYTE CORP Principal Accounting Officer Tray Thomas had 477 shares of common stock withheld on a recent restricted stock unit settlement. These shares were automatically retained by the company to cover tax withholding obligations, not sold on the open market. After this tax-withholding disposition, Thomas directly holds 20,655 shares, including 14,128 shares tied to unvested restricted stock units.
INCYTE CORP Chief Executive Officer and President William Meury reported a routine tax-related share disposition. On July 2, 2026, 4,779 shares of common stock were withheld at $116.86 per share to cover tax obligations tied to previously granted RSUs and earned performance shares.
After this automatic withholding, Meury directly owns 156,322 shares of common stock. Footnotes state this total includes 152,076 shares issuable from restricted stock units and earned performance shares that have not yet vested, highlighting that most of his reported position remains unvested equity awards rather than freely tradable shares.
INCYTE CORP chief medical officer Steven H. Stein reported an automatic share withholding to cover taxes tied to equity compensation. On this Form 4, 2,177 shares of common stock were withheld at an indicated value of $116.86 per share to satisfy tax withholding obligations when restricted stock units or earned performance shares settled.
After this tax-withholding disposition, Stein directly holds 76,150 shares of common stock. Footnote disclosure adds that his position also includes 73,591 shares of common stock underlying previously reported restricted stock units and earned performance shares that have not yet vested. This event reflects compensation-related tax treatment rather than an open-market sale.
Incyte Corporation has completed its acquisition of Vega Therapeutics, Inc., a wholly owned subsidiary of Star Therapeutics LLC, for an upfront payment of $1.25 billion. Star Therapeutics may receive up to an additional $750 million in sales milestone payments. The deal adds VGA039, an investigational monoclonal antibody in Phase 3 development for von Willebrand disease, to Incyte’s hematology portfolio and late-stage pipeline. VGA039 is being developed as a once-monthly subcutaneous prophylactic therapy and has received multiple U.S. FDA designations, including Breakthrough Therapy, Fast Track, orphan drug and rare pediatric disease. Incyte expects to record the transaction as a one-time R&D expense in its third-quarter and full-year 2026 GAAP and non-GAAP results.